Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials.
Sumit Mahato, Shiv Mudgal, Harminder Singh et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and network meta-analysis evaluated the efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors (TKIs) in treatment-naïve patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC). The analysis included nine randomized controlled trials. Dacomitinib and osimertinib demonstrated significant overall survival benefits compared to first-generation TKIs, with hazard ratios of 0.75 and 0.80, respectively.
Key findings
- Dacomitinib showed a significant overall survival benefit with HR 0.75 compared to first-generation TKIs.
- Osimertinib also demonstrated significant overall survival improvement with HR 0.80 versus first-generation TKIs.
- Furmonertinib had the highest P-score for progression-free survival, with HR 0.44.
- No significant differences in grade ≥ 3 adverse events were found among the EGFR-TKIs.
Why it matters
Understanding the comparative efficacy and safety of EGFR-TKIs is crucial for optimizing treatment strategies in patients with advanced NSCLC. This analysis provides insights into which agents may offer better outcomes, guiding clinical decision-making.